FDA Clearance Tracker · P910056-S027
enVista One-Piece Hydrophobic Acrylic Toric Intraocular Lens (Model MX60T)
Last checked: Nov 20, 2026Latest source record: Jun 8, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jun 8, 2018
Approved
Time to decision
221 days
Received Oct 30, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P910056-S027
- Device name
- enVista One-Piece Hydrophobic Acrylic Toric Intraocular Lens (Model MX60T)
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- Oct 30, 2017
- Decided
- Jun 8, 2018
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P910056
Device type
- Device type
- LENS, INTRAOCULAR, TORIC OPTICS (MJP)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the enVista One-Piece Hydrophobic Acrylic Toric Intraocular Lens (Model MX60T). The device is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens for improved uncorrected distance vision.
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
P240005 · Decided Oct 10, 2024 · 216 days after receipt
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.